

# Anti-Hemoglobin A [EPR3608]

G ( ) N			
Catalog No.	Description		
	6 ml of Ready-to-Use Antibody for use with		
AN977-5M	BioGenex Super Sensitive <sup>TM</sup> Detection		
	Systems OR equivalent detection system		
	10 ml of Ready-to-Use Antibody in a		
AN977-10M	barcode labeled vial for use with BioGenex		
AINTITUM	Super Sensitive <sup>TM</sup> Detection Systems and		
	i6000 <sup>TM</sup> Automated Staining Systems		
	1 ml of Concentrated Antibody for use with		
NU977-UC	BioGenex Super Sensitive <sup>TM</sup> Detection		
	Systems OR equivalent detection system		
	0.5 ml of Concentrated Antibody for use		
NU977-5UC	with BioGenex Super Sensitive <sup>TM</sup> Detection		
	Systems OR equivalent detection system		
	Ready-to-Use Antibody in Barcode labeled		
AY977-YCD	vial for use on the Xmatrx <sup>®</sup> Elite/Ultra		
	Staining System, 160 tests		
	Ready-to-Use Antibody in Barcode labeled		
AY977-50D	vial for use on the Xmatrx <sup>®</sup> Elite/Ultra		
	Staining System, 50 tests		

Clone	Species	Ig Class
EPR3608	Rabbit	IgG

#### **Intended Use**

**For In Vitro Diagnostic Use.** This antibody is designed for the specific localization of Hemoglobin in formalin-fixed, paraffinembedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

### **Summary and Explanation**

The human alpha globin gene cluster located on chromosome 16 spans about 30 kb and includes seven loci: 5'- zeta - pseudozeta - mu - pseudoalpha-1 - alpha-2 - alpha-1 - theta - 3'. The alpha-2 (HBA2) and alpha-1 (HBA1) coding sequences are identical and only differ slightly over the 5' untranslated regions and the introns (although they differ significantly over the 3' untranslated regions). Two alpha chains plus two beta chains constitute HbA, which in normal adult life comprises about 97% of the total hemoglobin; alpha chains combine with delta chains to constitute HbA-2, which with HbF (fetal hemoglobin) makes up the remaining 3% of adult hemoglobin. A reduction in the production of normal alpha globin chains results in inherited hematologic disorders such as alpha thalassemia whereby there is an increase in beta chains to compensate for the lack of normal alpha globin chains.

## **Storage and Handling**

**Store at 2-8°C.** Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

# Emergo Europe, Prinsessegracht 20, 2514AP The Hague, The Netherlands

# **Principles of the Procedure**

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The <u>primary antibody</u> may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

# **Reagents Provided**

Rabbit Monoclonal Antibody Hemoglobin Ais affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

# **Dilution of Primary Antibody**

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

#### **Recommended Protocol**

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations	
Control Tissue	Spleen tissue as available with Biogenex FB-977NE* & FG- 977NE*	
Recommended Dilution for Concentrated Antibody	1:10-25 in HK941	
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)	
Recommended	EZ-AR2 Elegance	
Pretreatment (Xmatrx)	(HX032-YCD)	
Antibody Incubation (Manual/i6000)	30-60 Min at RT	
Antibody Incubation (Xmatrx)	45-60 Min at 25°C	
	Use BioGenex Two-Step <b>OR</b>	
Detection System for	One-Step Super Sensitive <sup>TM</sup>	
Manual, Xmatrx & i6000	Polymer-HRP IHC Detection	
systems***	System/DAB; see p. 2 for more information	

<sup>\*</sup>FB: positive control micro chamber slides, FG: positive control microscopic slides. Xmatrx requires micro chamber slides.

Category	Antibodies	Revision No.	F
Document No.	932-977N-EN	Release Date	12-Nov-2021

<sup>\*\*</sup>Pretreatment times will vary based on individual microwave power.

\*\*\*For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit
Manual	QD440-XAKE (1000 Test) QD430-XAKE (1000 Test)	QD630-XAKE (1000 Test)	QP300-XAKE (1000 Test)
Manual	QD420-YIKE (500 Test) QD400-60KE (60 Test)	QD620-XAKE (500 Test)	QP900-9LE (500 Test)
Xmatrx - Automation	QD550-YCDE (200 Test)	QD610-YADE (200 Test)	N/A
i6000 - Automation	QD410-YAXE (200 Test)	QD610-YAXE (200 Test)	N/A
For more information, visit <u>www.biogenex.com</u> .			

#### **Precautions**

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

# **Quality Control**

Refer to BioGenex detection system documents for guidance on general quality control procedures.

# **Troubleshooting**

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

#### **Expected Results**

This antibody stains membrane /cytoplasm in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medicallyestablished diagnostic product or procedure.

# **Limitations of the Procedure**

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

# **Bibliography**

- 1. Woon-Shick, A et al. Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci. 2005 Mar; 96(3):197-201.
- 2. Abdullah, et al. The Free Alpha-Hemoglobin: A Promising Biomarker for β-Thalassemia. J MolBiomarkDiagn 2014, 5:5.
- 3. Petrakos, G. Pregnancy in women with thalassemia: challenges and solutions. Int J Womens Health. 2016 Sep 8; 8:441-51.
- 4. Nathan, GB & Gunn, RB. Thalassemia: the consequences of unbalanced hemoglobin synthesis. Am J Med. 1966 Nov; 41(5):815-3.

2°C 8°C	Temperature Limitation	IVD	In Vitro Diagnostic Medical Device
$\boxtimes$	Use By Date	LOT	Batch Code
NON STERILE	Non-Sterile	[]i	Consult Instructions for Use
EC REP	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	F
Document No.	932-977N-EN	Release Date	12-Nov-2021